Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Minocycline for opioid-associated central sleep apnoea and opioid tolerance
ACTRN12613000274774Phase 2Recruiting
- Sponsor
- Repatriation General Hospital
- Start
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of minocycline in central sleep apnea (CSA) and chronic pain, sponsored by Repatriation General Hospital. Primary endpoint: Proportion of patients with central apnoea index less than 5 per hour. Started Mar 2013; status: recruiting.
02
Drugs
minocycline
03
Conditions
central sleep apnea (CSA)chronic pain
Beyond the preview
Go deeper on ACTRN12613000274774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000274774.